Sarcoma Care
2025-07-24 19:00 - 20:30 (Africa/Nairobi)
Bridging Gaps in Soft Tissue Sarcoma Care
Date: 24 July 2025 | 7:00 – 8:30pm EAT
Moderator: Dr Rose Munge
Dr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa
Soft tissue sarcomas are rare malignant tumors of mesenchymal origin, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm), high recurrence (78%), and better outcomes with radical excisions.
Chemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However, access to radiotherapy remains limited, impacting outcomes. Timely radiotherapy, as seen in Tanzania, improves survival.
Key gaps include limited resources, lack of local treatment guidelines, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers, local research, and developing Africa-specific management guidelines.

Bone Marrow Transplant
2025-07-31 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Date: 31 July 2025 | 7:00 – 8:30PM EAT
Moderator: Dr Matilda Ongondi
Dr. Rohini Radia – Bone Marrow Transplantation
Bone marrow transplantation (BMT) is a potentially curative treatment for various blood cancers and benign hematologic conditions like sickle cell disease and aplastic anemia. It involves high-risk procedures requiring meticulous planning and long-term follow-up.
There are two main types:
Autologous (using the patient’s own cells) and Allogeneic (using donor cells). Allogeneic BMT carries a higher treatment-related mortality (10–25%) and risk of complications such as graft-versus-host disease (GVHD), infections, and infertility, but it is the only curative option for several conditions. Autologous BMT is safer (TRM <5%) and commonly used in myeloma and lymphomas.
Patient and donor selection, conditioning protocols, and GVHD prophylaxis are tailored individually. Long-term follow-up is essential, especially due to chronic GVHD and relapse risks. In sickle cell disease, allogeneic HSCT offers a potential cure but requires careful risk-benefit consideration.
Success in BMT depends on early identification, thorough preparation, and sustained multidisciplinary care beyond the immediate post-transplant period.

Cervical Cancer
2025-08-07 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Speakers:

Dr. Dulcie Wanda

Clinical & Radiation Oncologist
Head of Department, Nakuru Regional Cancer Treatment Centre

Topic: Radiotherapy in Management of Advanced Cancer of the Cervix.
2. Dr. Edward Sang

Gynaecologist and Oncologist, MP Shah Doctors Plaza, Nairobi

Topic: Surgical Techniques in Cervical Cancer
Moderator:
Dr. Afrin Fatima Shaffi

Gynecologic Oncologist, Nairobi West Hospital

Cancer Care
2025-08-28 19:00 - 19:30
Moderator:

Dr. Anne Mwirigi – Consultant Haematologist & Assistant Professor, Aga Khan University Hospital, Nairobi

Speakers:

Dr. Arjun Ghosh – Consultant Cardiologist, Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London & University College London Hospital
Dr. Manel Haj Mansour – Consultant Medical Oncologist & Section Head of Medical Oncology, Aga Khan University Hospital, Nairobi
Dr. Charles Kariuki – Interventional Cardiologist, Ubora Heart, The Nairobi Hospital
Dr. Gladwell Kiarie – Medical Oncologist, The Nairobi Hospital

Paediatric Bone Marrow Transplantation
2025-09-04 19:00 - 20:30
Date & Time:📅 4th September 2025🕖 7:00 PM – 8:30 PM (EAT)
Moderator:Dr. Robert KimutaiConsultant Paediatrician & Haematologist-Oncologist,MP Shah Hospital, Nairobi
Speaker:Dr. Brian NderuConsultant Paediatrician & Haematologist-Oncologist,Gertrude’s Children’s Hospital, NairobiTopic: Paediatric Bone Marrow Transplant: Immense Possibilities

Palliative Support and Pain Management
2025-09-11 19:00 - 20:30
Moderator:

Dr. Zipporah Ali – Palliative Care Physician and Public Health Specialist

Speakers:

Dr. Lee Ngugi – Pain Management Specialist, Anaesthesiologist & Lecturer, Kenyatta University, School of Medicine, NairobiTopic: Interventional Pain Management Procedures in Cancer-Related Pain
Dr. Esther Munyoro – Neuro-anaesthetist & Palliative Care Specialist, Former Head of Pain and Palliative Care Unit, Kenyatta National Hospital, NairobiTopic: Palliative care: Making it real

Management of CML Blast Crisis
2025-09-18 19:00 - 20:30
MANAGEMENT OF CML Blast Crisis
📅 Date: 18th September 2025⏰ Time: 7 PM – 8:30 PM EAT
MODERATORDr. Angela McligeyoPhysician and Medical Oncologist
SPEAKERProfessor Gianantonio RostiIRCCS IRST “Dino Amadori”, Meldola (Italy)Managing CML in Blast Crisis When Intensive Treatment Options are Available
SPEAKERProfessor Malkit RiyatAssociate Professor of Haematology & Consultant Haematologist, Aga Khan University Hospital, NairobiManaging CML in Blast Crisis When Intensive Treatment Options are Limited

Prostate Cancer Awareness
2025-09-25 19:00 - 20:30
Theme: Advancing Prostate Cancer Awareness
Date: 25th September 2025
Time: 7 PM – 8:30 PM EAT

Moderator: Prof. Mungai Ngugi (Consultant Urologist & Transplant Surgeon, Upper Hill Medical Center & Director, East Africa Kidney Institute)
Speakers:

H.E. Prof. Peter Anyang’ Nyong’o (Governor, Kisumu County)
Dr. Amina K. Habib (Medical Oncologist, Aga Khan University Hospital, Nairobi)
Prof. Nicholas Othieno Abinya (Professor of Medicine, Medical Oncologist, The Nairobi Hospital)

Organizers/Sponsors:

Kenya Society of Haematology & Oncology (KESHO)

Triple Negative Breast Cancer
2025-10-02 19:00 - 20:30
Triple Negative Breast Cancer: Early and Late Stage Management(CPD Accredited)
Date & Time:

2nd October 2025
7 PM – 8:30 PM (EAT)

Speaker: Dr. Joseph AbuodhaConsultant Medical Oncologist, Department of Haematology and Oncology, Aga Khan University Hospital, NairobiTopic: Triple-Negative Breast Cancer: Advancing Care Across Early and Late Stages
Moderator: Dr. Helena MusauConsultant Clinical/Radiation Oncologist and Palliative Care Specialist
Summary:
Triple-Negative Breast Cancer: Contemporary Clinical Updates
Presentation by Dr Joseph Abuodha

Dr Joseph Abuodha, Consultant Medical Oncologist, delivered a comprehensive clinical update on the biology, diagnosis and management of triple-negative breast cancer (TNBC), highlighting its aggressive nature, molecular heterogeneity and disproportionate burden in African populations.
The presentation outlined the distinctive pathological and molecular characteristics of TNBC, emphasizing the absence of hormone receptor and HER2 expression, high-grade histology and frequent genomic instability. Local and global epidemiological data were reviewed, underscoring the higher prevalence and mortality associated with TNBC in African and African-descended populations.
Management strategies across the disease spectrum were discussed, with chemotherapy reaffirmed as the backbone of treatment in non-metastatic disease. Dr Abuodha highlighted the growing role of neoadjuvant therapy, particularly for stage II and III disease, noting that achievement of pathologic complete response (pCR) remains a critical prognostic marker. Evidence supporting the incorporation of platinum agents and immune checkpoint inhibitors in selected patients was reviewed, alongside adjuvant strategies for residual disease, including capecitabine and PARP inhibitors in BRCA-mutated cancers.
In the metastatic setting, the importance of repeat biopsy and molecular reassessment was emphasized to guide therapy. Emerging systemic options including immunotherapy, PARP inhibitors and antibody–drug conjugates were discussed in the context of treatment sequencing and patient selection, alongside the central role of supportive and palliative care.
Key takeaway: Triple-negative breast cancer requires a biologically informed, stage-adapted treatment approach, with increasing emphasis on neoadjuvant strategies, molecular testing and integration of novel systemic therapies to improve outcomes in high-risk populations.

Advancing Care in HER2 Positive Breast Cancer
2025-10-15 08:00 - 17:00
Date: 9th October 2025
Time: 7 PM – 8:30 PM (EAT)CPD Accredited

Speakers

Dr. Manel Haj MansourConsultant Medical Oncologist & Section Head of Medical Oncology, Aga Khan University Hospital, NairobiTopic: Early and Locally Advanced HER2 Positive Breast Cancer — Evolving Strategies in Diagnosis, Treatment, and Long-Term Outcomes.

Dr. Angela McligeyoPhysician and Medical OncologistTopic: Metastatic HER2 Positive Breast Cancer — Optimizing Outcomes Through Novel Therapies and Multidisciplinary Care.

Moderator

Dr. Catherine NyongesaDirector of Medical Services, Kenyatta National Hospital & Co-founder, Texas Cancer Centre, Nairobi.

Digital Health: A Breast Cancer Journey
2025-10-21 19:00 - 20:30
Date: 21st October 2025
Time: 7 PM – 8:30 PM (EAT)
CPD Accredited

Moderator:

Dr. Sitna Ali Mwanzi – Consultant Medical Oncologist, Kenyatta National Hospital

Speakers:

Dr. Matiko Riro – Health Economist & CEO, Savannah Global Health Institute (SGHI)Topic: The Role of Data in Health Financing for Oncology – Use case Herceptin SC Access program
Dr. Ngure Nyaga – Healthcare Innovator & Technologist, Savannah InformaticsTopic: Leveraging Digital Solutions, Data & AI to Optimise Patient Outcomes in Oncology
Dr. Gladwell Kiarie – Medical Oncologist, The Nairobi HospitalTopic: Optimising Outcomes in Cancer Care – The Breast Cancer Patient Journey

Advancing Breast Cancer Survivorship Care in Kenya
2025-10-23 19:00 - 20:30
Theme: Evidence, Outcomes & Psychosocial PerspectivesDate: 23rd October 2025Time: 7:00 PM – 8:30 PM EATCPD Accredited
Speakers & Topics:
1. Zahra Haji

Psycho-oncologist & Associate Scientist
Psychosocial Oncology Lead, DART Lead Kenya; Aga Khan University Hospital Nairobi
Topic: The Emotional Journey of Survivorship: Addressing Psychological Well-being after Breast Cancer

2. Prisca Githuka

Vice-Chairperson & Advocacy Chair, Kenyan Network of Cancer Organizations (KENCO); Chairlady, Cancer Survivors Association of Kenya; Founder and Team Leader – Pink Hearts Cancer Support Foundation
Topic: Lived Experience of Breast Cancer Survivors in Kenya: Gaps and Implications for Care

3. Dr. Joyfrida Chepchumba

Pharmacist & Program Officer – Treatment, Palliative Care and Survivorship Pillar, National Cancer Control Program
Topic: Policy Frameworks for Breast Cancer Survivorship Care in Kenya

4. Lyagamula (Gammy) Kisia

Research Officer, African Population and Health Research Center (APHRC), Kenya
Topic: Breast Cancer Survivorship in Kenya: Key Findings from a Pilot Study

Moderator: Dr. Miriam Mutebi

Consultant Breast Surgical Oncologist & Health Systems Researcher, Aga Khan University in Nairobi, Kenya

Organizers & Partners:

KESHO (Kenya Society of Hematology & Oncology)
NCCP (National Cancer Control Programme)
KILELE Health Association
KENCO (Kenyan Network of Cancer Organizations)
APHRC (African Population and Health Research Center)

Multidisciplinary Management of Hepatocellular Carcinoma
2025-10-30 19:00 - 20:30
Multidisciplinary Management of Hepatocellular Carcinoma(CPD Accredited)
Date: 30th October 2025Time: 7:00 PM – 8:30 PM EAT
Moderator:Dr. Wycliffe KaishaConsultant Gastrointestinal & Hepato-Bilio-Pancreatic Surgeon, Hercules Healthcare
Speakers:

Dr. Gladwell KiarieMedical Oncologist, The Nairobi HospitalTopic: The Medical Oncologists’ Role in HCC: Emerging Trends
Dr. Eric MurungaConsultant Physician, Gastroenterologist; Chairman, Gastroenterology Society of KenyaTopic: Management of Hepatitis B in Low-Resource Settings
Dr. Samuel NgukuConsultant, Radiology and Nuclear Medicine, Aga Khan University Hospital, NairobiTopic: Imaging of Hepatocellular Carcinoma

Organized by:Kenya Society of Haematology & Oncology (KESHO)
Partner:Beacon Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
The Chronic Liver Disease–Hepatocellular Carcinoma Continuum: Practical Clinical Updates
Presentations by Dr Gladwell Kiarie and Dr Eric Murunga
Two complementary presentations examined the clinical continuum linking chronic liver disease to hepatocellular carcinoma (HCC), with a focus on pragmatic, evidence-based approaches applicable to resource-limited settings.
Dr Gladwell Kiarie reviewed the medical management of hepatocellular carcinoma, emphasizing the importance of stage-guided, individualized care. Using established staging frameworks, she highlighted how tumor burden, liver function and patient performance status collectively inform treatment selection. The discussion underscored the evolving role of systemic therapies, including immunotherapy and targeted agents, alongside locoregional modalities such as trans arterial therapies and radiotherapy. The need for multidisciplinary decision-making, early referral and appropriate patient selection was reinforced as critical to improving outcomes in HCC.
Dr Eric Murunga addressed the management of chronic Hepatitis B within real-world, resource-constrained contexts. He outlined practical diagnostic pathways, treatment eligibility criteria and monitoring strategies aligned with contemporary guidelines. Emphasis was placed on simplified fibrosis assessment tools, long-term antiviral therapy and structured follow-up. Preventive strategies including screening, vaccination of contacts and hepatocellular carcinoma surveillance were highlighted as essential interventions to reduce progression to cirrhosis and liver cancer.
Together, the presentations reinforced the concept that HCC prevention and outcomes are intrinsically linked to effective upstream management of chronic liver disease, particularly viral hepatitis.
Key takeaway: Strengthening early identification and treatment of chronic Hepatitis B, alongside structured surveillance and stage-appropriate management of hepatocellular carcinoma, is central to reducing advanced liver cancer and improving survival in resource-limited settings.

Advances in Small-Cell Lung Cancer Treatment
2025-11-13 19:00 - 20:30
Date: 13th November 2025Time: 7 PM – 8:30 PM EAT

SpeakerDr. Riaz KasmaniMedical Oncologist, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances, Evidence and Clinical Challenges

ModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head, Pulmonology, Aga Khan Hospital

Organized by:KESHOKenya Society of Haematology & Oncology
Supported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
Dr Kasmani presented an overview of Small Cell Lung Cancer (SCLC), focusing on disease biology, treatment response, relapse patterns and emerging research directions.
SCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive, with high response rates to first-line therapy, relapse is common and subsequent responses are often short-lived.
The presentation highlighted current staging approaches, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment, patterns of relapse and the clinical distinction between sensitive and refractory disease, which continues to guide second-line treatment decisions.
Key takeaway: Despite high initial response rates, SCLC remains a challenging disease with frequent relapses, underscoring the need for timely diagnosis, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.

Management of Non-Small Cell Lung Cancer
2025-11-20 19:00 - 2025-11-22 20:30
BRIDGING DISCIPLINES:ADVANCES IN THE COMPREHENSIVEManagement of Non-Small Cell Lung Cancer
Date: 20th November 2025Time: 7 PM – 8:30 PM EAT
(CPD ACCREDITED)

Moderator
Dr. Muhindi WanjuguPhysician and Chest Specialist, The Nairobi Hospital, Doctors Plaza, Nairobi

Speakers
Dr. Nuruddin JoomaHaemato-Oncologist, Florida Cancer Specialists & Research Institute, USASystemic Therapy Advances in Non-Small-Cell Lung Cancer
Dr. Morris MuhingaConsultant Cardiothoracic Surgeon, The Nairobi HospitalShift in Surgical Paradigm
Summary:
Lung Cancer: Contemporary Clinical Management and Emerging Evidence
Presentations by Dr Nuruddin Jooma and Dr Morris Muhinga
The sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing.
Key clinical principles discussed included optimal diagnostic pathways incorporating imaging, histopathology and immunohistochemistry, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection, avoid inappropriate use of immunotherapy and improve survival outcomes.
Current standards of care were reviewed across disease stages, including surgical management in early-stage disease, the expanding role of neoadjuvant and adjuvant systemic therapies, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms.
Both presentations reinforced the need for timely diagnosis, biomarker-driven treatment decisions and coordinated multidisciplinary care, while acknowledging ongoing challenges related to access, treatment sequencing and long-term disease control.
Key takeaway: Optimal lung cancer outcomes depend on precise staging, comprehensive molecular testing and evidence-based, multidisciplinary treatment across the disease continuum.

Management of Pancreatic Cancer
2025-11-27 19:00 - 20:30
CPD ACCREDITED
Management of Pancreatic Cancer
Date:27th November 2025
Time:7 PM – 8:30 PM EAT

Moderator
Dr. Karan GandhiConsultant Hepatobiliary, General and Laparoscopic Surgeon at 3rd Park Hospital, Nairobi

SPEAKER
Dr. Sakulen A HarguraConsultant Hepatobiliary, General & Laparoscopic Surgeon, Kenyatta University Teaching, Research and Referral Hospital, NairobiTopic: Surgical Dilemmas in Pancreatic Cancer, “Who, When & How”

SPEAKER
Dr. Andrew OdhiamboMedical Oncologist – The Nairobi HospitalThematic Head & Program Director – Medical Oncology, UONTopic: Balancing Quality Vs Quantity of Life – Oncologist Role in Stage 4 Pancreatic Cancer
SPEAKER
Joyce AwuorConsultant Dietitian Nutritionist, Founder and CEO of DietSelect254Topic: The Ideal Diet for A Failing Pancreas
KESHOKenya Society of Haematology & Oncology

Cancer-Related Thrombosis
2025-12-04 19:00 - 20:30
Cancer-Associated Thrombosis: From Primary to Secondary Prophylaxis
Presentation by Dr Laura Kirui
Dr Laura Kirui delivered a focused clinical update on cancer-associated thrombosis (CAT), addressing its epidemiology, pathophysiology and evidence-based prevention and treatment strategies across the cancer care continuum.
The presentation highlighted the significantly increased risk of venous thromboembolism (VTE) among cancer patients and its associated morbidity and mortality. Mechanistic insights into cancer-driven hypercoagulability including inflammation, dysregulated fibrinolysis, and tumor host cellular interactions were reviewed to contextualize clinical risk.
Emphasis was placed on risk stratification, particularly the use of validated tools such as the Khorana score, to guide decisions on primary thromboprophylaxis. Data supporting the use of low molecular weight heparin and selected direct oral anticoagulants in high-risk populations were discussed, alongside bleeding considerations. The session also addressed therapeutic anticoagulation, duration of treatment, secondary prophylaxis and management in special scenarios including thrombocytopenia, catheter-related thrombosis and incidental VTE.
Key takeaway: Individualized risk assessment and ongoing reassessment are central to optimizing prevention and management of cancer-associated thrombosis.

Bladder and Urothelial Cancer Treatment
2025-12-11 19:00 - 20:30
Moderator:
Dr. Thomas OdenyMedical Oncologist, Assistant Professor of Medicine,Washington University in St. Louis
Speakers:
Dr. Primus OchiengLecturer, Programme Director – MMed Radiation Oncology& Founder, UNITED Oncology Clinical Trial Centre, UoNRadiotherapy in Bladder Cancer: Current Evidence and Clinical Applications
Dr. DK KimaniConsultant Surgeon & Urologist, Kenyatta National Hospital, NairobiBladder & Urothelial Cancer in Kenya: Bridging Treatment Innovations and Local Realities
Dr. Andrea ApolloSenior Investigator, Genitourinary Malignancies Branch, NCI, USAManagement of bladder cancer: Clinical trials and research updates

Multiple Myeloma
2025-12-22 08:00 - 17:00

Cervical Cancer Prevention and Control In Kenya
2026-01-22 19:00 - 20:30
(CPD Accredited)
Date & Time: 22nd January 2026 7 PM – 8:30 PM (EAT)

Moderator: Dr. Benjamin Elly Odongo
Obstetrician/Gynecologist & Gynaecologic Oncologist, Senior Lecturer & Chairman, Department of Obstetrics & Gynaecology, Kenyatta University School of Health Sciences

Speakers:
Prof. Lucy Muchiri
Associate Professor in the Department of Human Pathology, University of Nairobi’s School of Medicine
Topic: Overview of the WHO 90-70-90 cervical cancer elimination strategy and implications for pathology services
Prof. Omu Anzala Professor of Virology and Immunology, Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI – ICR), University of Nairobi, Kenya
Topic: HPV Vaccination in Kenya: Scientific Evidence, Immunological Perspectives, and Public Controversies
Dr. Richa Bansal Gynecological Oncologist and Robotic Surgeon, Apollo Hospitals, Navi Mumbai, India
Topic: Cervical Cancer Prevention and Advanced Treatment
Highlights
This session examined cervical cancer through the lens of prevention, highlighting it as one of the few cancers where elimination is both feasible and within reach.
A central theme was the WHO 90-70-90 strategy, which outlines a clear pathway to elimination through HPV vaccination, screening and timely treatment. Achieving these targets could reduce cervical cancer incidence to below 4 cases per 100,000 women, effectively transforming it into a rare disease.
The discussion emphasized that cervical cancer is almost entirely driven by persistent HPV infection, making it uniquely preventable through vaccination and early detection. Evidence shows that HPV vaccines are highly effective, with strong and sustained protection against high-risk HPV types responsible for most cases.
Despite this, the burden remains disproportionately high in low- and middle-income settings, including Kenya, where gaps in screening coverage, diagnostic capacity and referral pathways continue to limit early detection and timely treatment.
The role of pathology services emerged as critical, forming the diagnostic backbone for screening programs and treatment decisions. Expanding HPV DNA testing, strengthening laboratory systems and investing in workforce development were identified as key priorities for achieving national targets.
Across the session, a consistent message emerged: cervical cancer is preventable and eliminating it will depend on scaling what already works.
Key Takeaways

Cervical cancer is one of the few cancers where elimination is achievable.
The WHO 90-70-90 targets provide a clear, evidence-based roadmap.
HPV vaccination and screening are high-impact prevention strategies.
Strengthening pathology and diagnostic capacity is essential to progress.
Closing gaps in access and coverage is critical to achieving equitable outcomes.

HPV Vaccine Campaign/Outreach Screening
2026-01-31 08:00 - 17:00

World Cancer Day
2026-02-05 19:00 - 20:30 | Virtual Event (Zoom), Kenya
World Cancer Day:
United by Unique – The Kenyan Perspective
Date: 5th February 2025Time: 7:00 PM – 8:30 PM (EAT)
Moderator
Dr. Gladwell KiarieMedical Oncologist, The Nairobi Hospital
Speakers
Hon. Dr. Ouma OlugaPrincipal Secretary for the State Department for Medical Services,Ministry of Health, Kenya
Hon. Dr. James NyikalChairperson of the National Assembly Departmental Committee on Health, Kenya
Dr. Mercy MwangangiChief Executive Officer, Social Health Authority
Dr. Elias MellyChief Executive Officer, National Cancer Institute, Kenya
Dr. Ahmed OgwellPublic Health Expert, CEO & President, VillageReach
Prisca GithukaVice-Chairperson & Advocacy Chair,Kenyan Network of Cancer Organizations (KENCO) and Chairlady,Cancer Survivors Association of Kenya
Highlights
This session brought together clinical, policy and advocacy voices to reflect on the current state of cancer care in Kenya, with a focus on how systems, leadership and lived experience intersect to shape outcomes.
A central theme was the need to move beyond fragmented approaches towards coordinated, patient-centered cancer control, grounded in national priorities and responsive to the realities of care delivery. The discussion highlighted that improving outcomes requires not only clinical excellence, but also alignment across policy, financing and implementation.
Speakers emphasized the importance of strengthening health systems to support prevention, early detection and access to treatment, while addressing structural barriers that continue to limit equitable care. The role of national institutions, policy frameworks and cross-sector collaboration emerged as critical in driving sustainable progress.
Patient voice and lived experience were also highlighted as essential to shaping responsive and inclusive cancer care strategies, ensuring that interventions reflect the needs and realities of those most affected.
Across the discussion, a consistent message emerged: meaningful progress in cancer control will depend on alignment between policy, practice and people.
Key Takeaways

Effective cancer control requires alignment across clinical care, policy and implementation.
Strengthening health systems is essential to improving access, equity and outcomes.
Prevention and early detection remain critical entry points for reducing burden.
Patient voice and lived experience are key to responsive, person-centered care.
Sustainable progress depends on multi-sector collaboration and leadership.

Watch the full session here:

Watch Video

Environmental Risks of Cancer
2026-02-12 08:00 - 17:00
Speakers: Dr. Mary Nyangasi, Dr. David Githanga, Dr. Carolina Espina
Date: 12 February 2026
Highlights
This session examined cancer risk through an environmental and public health lens, highlighting the extent to which cancer burden is shaped by modifiable exposures rather than biology alone. A central theme was the recognition that cancer is not only a clinical or genetic condition, but also a social and environmental disease, with a substantial proportion of cases linked to preventable risk factors. Global evidence suggests that up to 40% of cancers are attributable to modified exposures, including environmental and occupational risks. Dr. Githanga outlined the biological mechanisms through which environmental exposures drive carcinogenesis, including DNA damage, chronic inflammation, epigenetic dysregulation and impaired immune surveillance. These pathways act cumulatively over time, often with long latency periods between exposure and disease manifestation.
Real-world examples such as air pollution, aflatoxin exposure and oncogenic infections illustrate how environmental context directly shapes cancer patterns, particularly in low- and middle-income settings where exposure levels are higher and regulatory systems less robust. Building on this, Dr. Nyangasi emphasized that a significant proportion of cancer burden is preventable, with WHO frameworks highlighting the importance of population-level interventions targeting modifiable risk factors, including environmental regulation, vaccination and lifestyle-related risks.
Dr. Espina introduced the World Code Against Cancer framework, which translates complex scientific evidence into clear, actionable recommendations for individuals, health systems and policymakers. The framework underscores the importance of moving beyond individual behavior change towards coordinated, multi-sectoral prevention strategies. Across the session, a consistent message emerged: meaningful reductions in cancer burden will depend on shifting upstream towards prevention, regulation and system-level action
Key Takeaways

A substantial proportion of cancers are linked to modifiable environmental and behavioral exposures.
Environmental carcinogenesis occurs through multi-pathway biological mechanisms over time.
Exposure to risk is uneven and shaped by social and economic conditions.
Population-level interventions have greater impact than individual behavior change alone.
Effective cancer control requires alignment between clinical practice, public health and policy.

Management of Biliary and Gall Bladder Tumours
2026-02-19 19:00 - 20:30
SUMMARY
Advances in the Multidisciplinary Management of Biliary and Gallbladder Tumours
Speakers: Prof. Elly Ogutu, Dr. Mohan Ramchandani, Dr. Kausik Bhattacharya, Dr. M. Vamshi Krishna
Date: 19 February 2026
This session examined the management of biliary and gallbladder tumours through a multidisciplinary lens, highlighting the importance of coordinated approaches across endoscopy, surgery and oncology in improving patient outcomes.
A central theme was the role of accurate and timely diagnosis, with particular emphasis on tissue acquisition and the contribution of advanced endoscopic techniques in guiding clinical decision-making. The discussion underscored how delays or limitations in diagnostic pathways can significantly influence treatment options and outcomes.
Through the KNH–UoN strategic training partnership and collaboration with the Asian Institute of Gastroenterology, the session reflected the value of regional expertise and diaspora engagement in strengthening clinical capacity and expanding access to specialised skills.
From a clinical perspective, evolving therapeutic strategies—including advances in surgical techniques and radiation oncology—were highlighted as critical components of care, particularly when integrated within a multidisciplinary framework that supports individualized treatment planning.
Across the session, a consistent message emerged: improving outcomes in biliary and gallbladder cancers will depend on strengthening diagnostic pathways and ensuring coordinated, multidisciplinary care across the patient journey.
Key Takeaways

Early and accurate diagnosis remains central to effective management.
Advanced endoscopic techniques play a key role in tissue sampling and staging.
Multidisciplinary coordination improves treatment planning and outcomes.
Regional and diaspora collaboration strengthens clinical capacity.
Integration of surgical, endoscopic and oncological care is essential.

Precision Pathways in Lymphoma
2026-02-26 19:00 - 20:30
Date: 26th February 2026Time: 7:00 PM – 8:30 PM (EAT)

Speakers
ModeratorDr Anne MwirigiConsultant Haematologist & Assistant Professor, AKUH
Dr Rohini RadiaConsultant in BMT and Haematology, Nairobi West HospitalStrategic Alignment in Lymphoma: From Precise Diagnosis to Clinical Excellence
Dr Jonathan WawireConsultant Anatomic Pathologist & Assistant Professor, AKUHLymphoma Diagnostic Algorithm in Routine Practice
Highlights
This session explored how lymphoma care is increasingly shaped by the alignment between diagnostic precision and therapeutic decision-making, particularly in settings where access to advanced diagnostics remains variable.
A central theme was the shift from morphology-led classification alone to a multi-parameter diagnostic approach, integrating clinical context, histopathology, immunophenotyping and where available, molecular profiling. As emphasized during the discussion, classification is no longer purely descriptive: it directly determines treatment pathways, prognosis and eligibility for emerging therapies.
Dr. Wawire outlined a structured diagnostic framework anchored on architecture, cytology and clonality, with morphology guiding the initial pathway and targeted immunohistochemistry refining classification. In routine practice, a focused IHC panel (CD20, CD3, CD5, CD10, Cyclin D1) remains sufficient to classify most lymphomas and support timely clinical decisions.
Importantly, the session addressed the practical realities of diagnostic limitations. The distinction between “Not Otherwise Specified (NOS)” and “Not Further Classified (NFC)” was highlighted as a clinically responsible approach where molecular testing is unavailable maintaining transparency while ensuring patients are still appropriately managed.
Building on this, Dr. Radia emphasized that improved outcomes depend on early alignment between diagnostics, treatment selection and delivery systems. In practice, delays in diagnostic workflows or limited access to molecular testing can directly influence treatment choices and patient outcomes making coordination across pathology, oncology and imaging essential.
As treatment options expand, from immunochemotherapy to targeted agents, CAR-T therapies and bispecific antibodies, the need for early risk stratification and timely decision-making becomes even more critical, particularly in balancing efficacy, cost and access within real-world settings.
Across the case discussions, a consistent message emerged: the quality and timeliness of diagnosis remain central to achieving better outcomes in lymphoma care.
Key takeaways:

Lymphoma classification now relies on integrated clinical, morphological and molecular assessment.
Focused IHC panels remain highly effective in routine and resource-limited settings.
“NFC” supports safe, transparent reporting when advanced testing is unavailable.
Diagnostic delays and access gaps can directly impact treatment decisions.
Early alignment across disciplines is essential to optimize outcomes.

Women in Oncology
2026-03-05 19:00 - 20:30
Women in Oncology this International Women’s Day!
Join us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology
Date: 5th March 2026
Time: 7:00 PM – 8:30 PM EAT
Moderator:

Dr. Gladwell Kiarie — Medical Oncologist, The Nairobi Hospital

Speakers:

Prof. Verna Vanderpuye

Senior Consultant Clinical Oncologist & Deputy Director, National Centre of Radiotherapy, Oncology and Nuclear Medicine, Korle-bu Teaching Hospital, Accra, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa

Dr. Chemtai Mungo

Assistant Professor of Obstetrics and Gynaecology & Physician-Scientist, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health, Research and Women’s Impact in Oncology

Dr. Anne Mwirigi

Consultant Haematologist and Assistant Professor, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology

Prof. Nazik Hammad

Professor of Medical Oncology, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship, Leadership and Equity in Cancer Care

Multiple Myeloma Care in Western Kenya
2026-03-12 19:00 - 20:30
Event Title: The Journey of Multiple Myeloma Care in Western Kenya
Accreditation: CPD Accredited

Date: 12th March 2026
Time: 7 PM – 8:30 PM EAT
Organization: KESHO (Kenya Society of Haematology & Oncology)

Moderator:

Dr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist, Kenyatta National Hospital.

Speakers

Dr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification
Dr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing, Cellular Therapies and Risk-Adapted Strategies
Dr. Beatrice Melly: Clinical Haematologist, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access, Infrastructure and Multidisciplinary Integration
Hightlights

This session examined how multiple myeloma care is evolving within the Kenyan context, bringing together perspectives on diagnostics, treatment advances and system-level delivery.
A central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors, immunomodulatory agents and anti-CD38 therapies, translating these gains into routine practice remains uneven.
The discussion highlighted the importance of accurate and timely diagnosis, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions.
From a clinical perspective, modern management is increasingly risk-adapted, incorporating quadruplet induction regimens, autologous stem cell transplantation and maintenance strategies. Emerging therapies, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease, though access remains limited in many settings.
At a systems level, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships, integrating clinical care, training and research within a learning health system. The approach emphasizes improving access, strengthening diagnostic and treatment infrastructure, and embedding multidisciplinary care pathways to support patients across the disease course.
Across the session, a consistent message emerged: advancing myeloma care requires not only better therapies, but systems capable of delivering them.
Key Takeaways

Myeloma outcomes are improving with novel and combination therapies.
Accurate diagnosis and risk stratification are central to management.
Standard care includes quadruplet induction, ASCT and maintenance therapy.
CAR-T and bispecific antibodies are reshaping relapsed disease care.
Sustainable progress depends on access, infrastructure and integrated care models.

Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
2026-03-19 19:00 - 20:30
Evidence-Based Integration of Surgery and Systemic Therapy
Date: 19th March 2026Time: 7 PM – 8:30 PM EAT
MODERATORDr. Amina K. HabibMedical Oncologist, Aga Khan University Hospital, Nairobi
Dr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma
Dr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma
Highlights
This session examined the evolving management of renal cell carcinoma (RCC), focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum.
A central theme was the importance of risk-adapted, multidisciplinary care, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally, late-stage presentation remains common in Kenya, shaping both prognosis and treatment strategy.
From a surgical perspective, nephron-sparing surgery remains standard for localized diseases, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients, particularly when integrated with systemic treatment strategies.
Systemic therapy has expanded significantly, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens, reinforcing a shift towards early and strategic use of systemic therapy, particularly in metastatic and high-risk settings.
In the adjuvant setting, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients, highlighting the importance of post-surgical risk stratification and follow-up.
However, translating these advances into routine practice remains constrained by access, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways, supported by multidisciplinary decision-making and strengthened health systems.
Across the session, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery, systemic therapy and patient-centered decision-making.
Key Takeaways

RCC management requires integration of surgical and systemic therapies.
Late-stage presentation remains a key challenge in many settings.
Nephron-sparing and radical surgery remain central to localized and advanced disease.
Immunotherapy and targeted agents are transforming metastatic RCC outcomes.
Adjuvant therapy is increasingly relevant in high-risk post-surgical patients.
Access, cost and infrastructure continue to shape real-world implementation.

Optimizing Care in Colorectal Cancer
2026-03-26 19:00 - 20:30
Date: 26th March 2026
Time: 7 PM – 8:30 PM EAT
Moderator

Dr. Andrew Odhiambo Medical Oncologist, The Nairobi Hospital; Thematic Head & Program Director, Medical Oncology, UON

Speakers
Dr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist, Kenyatta University Teaching, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment
Dr. Caroline Tonio Medical Oncologist, Clinical Research Fellow (Clinical Trials), The Christie NHS Foundation Trust, UK & KUTRRH, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact.

CLICK TO REGISTER

Treatment in Esophageal Cancer
2026-04-09 19:00 - 20:30
THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer
Date: 9th April 2026 Time: 7 PM – 8:30 PM EAT
MODERATOR
Dr. Omar Abdihamid Clinical Oncologist, Garissa Regional Cancer Center | Vice President (EA), African Organisation for Research and Training in Cancer
SPEAKERS
Dr. Juma Odoro Cardiothoracic and vascular surgeon, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer
Dr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer
Dr. Kevin Makori Consultant Clinical & Radiation Oncologist, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator, Victoria Cancer Care & Research Center, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies

CLICK TO REGISTER
